Slideshows Images Quizzes

Edarbyclor

Last reviewed on RxList: 6/15/2017
Edarbyclor Side Effects Center

Last reviewed on RxList 06/15/2017

Edarbyclor (azilsartan medoxomil and chlorthalidone) is a combination an angiotensin II receptor blocker (ARB) and a diuretic used to treat high blood pressure (hypertension). Common side effects of Edarbyclor include:

  • dizziness,
  • fatigue,
  • weakness,
  • tiredness,
  • skin rash,
  • diarrhea,
  • nausea,
  • upset stomach, or
  • cough.

Tell your doctor if you have serious side effects of Edarbyclor including:

  • feeling like you might pass out,
  • urinating less than usual or not at all,
  • drowsiness,
  • confusion,
  • mood changes,
  • increased thirst,
  • loss of appetite,
  • swelling,
  • weight gain,
  • feeling short of breath, or
  • electrolyte imbalance (dry mouth, extreme thirst, drowsiness, restless feeling, confusion, increased or decreased urination, constipation, muscle pain or weakness, fast heart rate, or seizures/convulsions).

The recommended starting dose of Edarbyclor is 40/12.5 mg taken orally once daily. Edarbyclor may interact with nonsteroidal anti-inflammatory drugs (NSAIDs), other angiotensin receptor blockers, ACE inhibitors, aliskiren, or lithium. Tell your doctor all medications and supplements you use. Edarbyclor is not recommended for use during pregnancy. It may harm a fetus. It is unknown if azilsartan passes into breast milk, but because of the potential for adverse effects on the nursing infant, consult your doctor before breastfeeding.

Our Edarbyclor (azilsartan medoxomil and chlorthalidone) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Edarbyclor Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • feeling like you might pass out;
  • urinating less than usual or not at all;
  • drowsiness, confusion, mood changes, increased thirst, loss of appetite;
  • swelling, weight gain, feeling short of breath; or
  • electrolyte imbalance (dry mouth, extreme thirst, drowsiness, restless feeling, confusion, increased or decreased urination, constipation, muscle pain or weakness, fast heart rate, or seizure (convulsions)).

Other common side effects may include:

  • mild skin rash;
  • diarrhea, nausea, upset stomach;
  • cough;
  • mild dizziness; or
  • weakness, tired feeling.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Edarbyclor (Azilsartan Medoxomil and Chlorthalidone Tablets)

Edarbyclor Professional Information

SIDE EFFECTS

The following potential adverse reactions with Edarbyclor, azilsartan medoxomil, or chlorthalidone and similar agents are included in more detail in the Warnings and Precautions section of the label:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Edarbyclor has been evaluated for safety in more than 3900 patients with hypertension; more than 700 patients were treated for at least 6 months and more than 280 for at least 1 year. Adverse reactions have generally been mild and transient in nature.

Common adverse reactions that occurred in the 8-week factorial design trial in at least 2% of Edarbyclor-treated patients and greater than azilsartan medoxomil or chlorthalidone are presented in Table 1.

Table 1. Adverse Reactions Occurring at an Incidence of ≥2% of Edarbyclor-treated Patients and > Azilsartan medoxomil or Chlorthalidone

Preferred Term Azilsartan medoxomil
20, 40, 80 mg
(N=470)
Chlorthalidone
12.5, 25 mg
(N=316)
Edarbyclor
40 / 12.5, 40 / 25 mg
(N=302)
Dizziness 1.7% 1.9% 8.9%
Fatigue 0.6% 1.3% 2.0%

Hypotension and syncope were reported in 1.7% and 0.3%, respectively, of patients treated with Edarbyclor.

Study discontinuation because of adverse reactions occurred in 8.3% of patients treated with the recommended doses of Edarbyclor compared with 3.2% of patients treated with azilsartan medoxomil and 3.2% of patients treated with chlorthalidone. The most common reasons for discontinuation of therapy with Edarbyclor were serum creatinine increased (3.6%) and dizziness (2.3%).

The adverse reaction profile obtained from 52 weeks of open-label combination therapy with azilsartan medoxomil plus chlorthalidone or Edarbyclor was similar to that observed during the double-blind, active controlled trials.

In 3 double-blind, active controlled, titration studies, in which Edarbyclor was titrated to higher doses in a step-wise manner, adverse reactions and discontinuations for adverse events were less frequent than in the fixed-dose factorial trial.

Azilsartan Medoxomil

A total of 4814 patients were evaluated for safety when treated with azilsartan medoxomil at doses of 20, 40 or 80 mg in clinical trials. This includes 1704 patients treated for at least 6 months, of these, 588 were treated for at least 1 year. Generally, adverse reactions were mild, not dose related and similar regardless of age, gender and race.

Adverse reactions with a plausible relationship to treatment that have been reported with an incidence of ≥0.3% and greater than placebo in more than 3300 patients treated with azilsartan medoxomil in controlled trials are listed below:

Gastrointestinal Disorders: diarrhea, nausea

General Disorders and Administration Site Conditions: asthenia, fatigue

Musculoskeletal and Connective Tissue Disorders: muscle spasm

Nervous System Disorders: dizziness, dizziness postural

Respiratory, Thoracic and Mediastinal Disorders: cough

Chlorthalidone

The following adverse reactions have been observed in clinical trials of chlorthalidone: rash, headache, dizziness, GI upset, and elevations of uric acid and cholesterol.

Clinical Laboratory Findings with Edarbyclor

In the factorial design trial, clinically relevant changes in standard laboratory parameters were uncommon with administration of the recommended doses of Edarbyclor.

Renal Parameters

Increased blood creatinine is a known pharmacologic effect of renin-angiotensin aldosterone system (RAAS) blockers, such as ARBs and ACE inhibitors, and is related to the magnitude of blood pressure reduction. The incidence of consecutive increases of creatinine ≥50% from baseline and >ULN was 2.0% in patients treated with the recommended doses of Edarbyclor compared with 0.4% and 0.3% with azilsartan medoxomil and chlorthalidone, respectively. Elevations of creatinine were typically transient, or non-progressive and reversible, and associated with large blood pressure reductions.

Mean increases in blood urea nitrogen (BUN) were observed with Edarbyclor (5.3 mg/dL) compared with azilsartan medoxomil (1.5 mg/dL) and with chlorthalidone (2.5 mg/dL).

Postmarketing Experience

The following adverse reactions have been identified during the postmarketing use of EDARBYCLOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the entire FDA prescribing information for Edarbyclor (Azilsartan Medoxomil and Chlorthalidone Tablets)

Related Resources for Edarbyclor

© Edarbyclor Patient Information is supplied by Cerner Multum, Inc. and Edarbyclor Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors